Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. It maintains over 70% of the sequencing market and specializes in providing instruments and tools to a variety of customers such as academic institutions and government, pharmaceutical, and biotechnology companies across the world. Companies may grow organically or through acquisition. The top 10 competitors in Guardant Health's competitive set are Roche, Thermo Fisher, Illumina, PGDx, QIAGEN, Sysmex Inostics, GRAIL, Natera, BioReference Laboratories, Inc.. Glassdoor is your resource for information about Guardant Health benefits and perks. Comparatively, 84.1% of Natera shares are held by institutional investors. How Guardant Health is Supporting Cancer Care During the Pandemic. Precision oncology company Guardant Health, buoyed by its Guardant360 assay for matching cancer patients with … Comparatively, CareDx has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. This field has transformed science and medicine, and its innovations have made some investors wealthy from its successes. Some of the competitors of Guardant Health are Genentech, Illumina, and Genomic Health. The companies' financial situations are similar, but Illumina has a larger growth opportunity once the COVID-19 impact settles. 76.2% of Guardant Health shares are held by institutional investors. Jackpot: Drills are Running Hot like Lava for this Company´s South American Super Project, These unique rock formations now host some of the highest-grade gold mineralization on the planet. 76.2% of Guardant Health shares are held by institutional investors. Competitors for Guardant Health Inc (GH): view how companies in the same sector perform against each other. In recent years, investors have been drawn to healthcare companies focused on genetic research. Fundamental company data provided by Morningstar and Zacks Investment Research. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Guardant Health (NASDAQ:GH) and Invitae (NYSE:NVTA) are both large-cap medical companies, but which is the superior investment? Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The traditional methods of detection occur after the cancer is suspected and involves the use of invasive procedures such as surgery to extract a sample, while liquid biopsies are simple blood tests that have the potential to detect cancer at earlier stages. Guardant Health is not providing 2020 financial guidance due to the continued uncertainties from the impact of COVID-19. Comparatively, Quest Diagnostics has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. MarketScreener. These liquid biopsy tests, which rely on next-generation DNA sequencing to better identify signs of cancer, have become increasingly popular in cancer diagnostics. Guardant Health (NASDAQ:GH) and Veracyte (NASDAQ:VCYT) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. 9.9% of Guardant Health shares are held by company insiders. In some cases apparently high growth rates may be caused by data that weren't available in previous years. Comparatively, Laboratory Co. of America has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Looking for new stock ideas? Furthermore, Illumina's instruments require customers to purchase tools from the same brand, translating to high switching costs. Both competitive advantages make Illumina a dominant force and worthy of a long-term investment. Let's conquer your financial goals together...faster. Guardant Health has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 Comparatively, Veracyte has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. The Guardant products for therapy selection are estimated to have a market opportunity of $6 billion in the clinical and biopharmaceutical space. Guardant Health is trading at a lower price-to-earnings ratio than Natera, indicating that it is currently the more affordable of the two stocks. Benefits information above is provided anonymously by current and former Guardant Health employees, and may include a summary provided by the employer. We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. Learn more. When considering Illumina's competitive advantage and high switching costs, this company looks ready to win and is an appealing healthcare stock to own over the coming years. See you at the top! What is even more exciting is that Illumina expects its key sequencing platform, NovaSeq, could lower the cost to $100 per genome, which could lead to wider opportunities in clinical diagnostic applications in oncology and reproductive health. Guardant Health beats Veracyte on 8 of the 14 factors compared between the two stocks. Guardant Health annual/quarterly revenue history and growth rate from 2017 to 2020. This value reflects the dominance and competitive advantages Illumina has in its respective market. Comparatively, 1.5% of Quest Diagnostics shares are held by company insiders. 76.2% of Guardant Health shares are owned by institutional investors. Natera has a consensus price target of $75.90, suggesting a potential downside of 23.31%. View our full suite of financial calendars and market data tables, all for free. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Management believes that there is an estimated market opportunity of over $50 billion in the U.S. Guardant currently offers two products, Guardant360 and GuardantOMNI, for advanced stage cancer. If you've got money invested in the stock market, but are confused as to what to do next...This is the can't miss interview of 2020. Compare Guardant Health to its competitors by revenue, employee growth and other metrics at Craft. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. This table compares Guardant Health and CareDx's gross revenue, earnings per share and valuation. Now FDA Approved. Data Sources: Yahoo Finance, Illumina, Guardant Health. Guardant Health has higher earnings, but lower revenue than Natera. Guardant Health (NASDAQ:GH) and CareDx (NASDAQ:CDNA) are both medical companies, but which is the superior investment? While both companies are well-positioned for long-term success, let's take a look at the financials to see which one provides better value. Market data powered by FactSet and Web Financial Group. Learn about Guardant Health , including insurance benefits, retirement benefits, and vacation policy. GuardantOMNI differs from Guardant360 in that biopharma companies use it for comprehensive genomic profiling in both immuno-oncology and targeted therapy areas. Clinicians use it to inform the selection of cancer therapy for their patients, whereas biopharmaceutical companies use it to accelerate drug development and commercialize products. Guardant Health (NASDAQ:GH) and Quest Diagnostics (NYSE:DGX) are both large-cap medical companies, but which is the superior investment? Receive a free world-class investing education from MarketBeat. This table compares Guardant Health and CareDx's net margins, return on equity and return on assets. Guardant Health has higher earnings, but lower revenue than Invitae. Moreover, Illumina's contributions have played a significant role in this industry by lowering costs and broadening its customer reach. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. This is a breakdown of current ratings and recommmendations for Guardant Health and Natera, as provided by MarketBeat.com. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. Germany's Qiagen sees solid growth in … Webcast Information. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. It posted non-GAAP earnings per share (EPS) of $1.64 beating the consensus estimates by $0.38. Learn everything you need to know about successful options trading with this three-part video course. Both companies have plenty of cash to operate, but Illumina commands a market valuation of $54.2 billion, nearly seven times the $7.9 billion market cap of Guardant Health. Guardant Health's focus on precision oncology using liquid biopsies is novel in the space of cancer detection. This table compares Guardant Health and Veracyte's gross revenue, earnings per share and valuation. 76.2% of Guardant Health shares are held by institutional investors. Guardant Health is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks. Should you be buying GH stock or one of its competitors? Learn more. Companies like Guardant Health. Guardant Health currently markets its tests in more than 40 countries outside the United States, primarily through distributor relationships and direct contracts with hospitals. Guardant Health IPO: 5 things to know about the startup that wants to detect cancer early ... New competitors could also emerge. Liquid biopsies have the potential to improve clinical outcomes, lower healthcare costs, and enable biopharma companies to advance new therapies. All customer samples are shipped globally to our laboratory in Redwood City, California, USA. Given Laboratory Co. of America's higher probable upside, analysts plainly believe Laboratory Co. of America is more favorable than Guardant Health. Veracyte has a consensus price target of $40.8333, suggesting a potential downside of 24.83%. Comparatively, 0.7% of Laboratory Co. of America shares are owned by insiders. Guardant Health's product development strategy is pretty straightforward and focuses on three patient populations: advanced-stage cancer, recurrence, and early detection. Get daily stock ideas top-performing Wall Street analysts. Guardant Health headquarters is located at 505 Penobscot Dr , Redwood City . Soon, it could detect cancer earlier than ever before. This is a breakdown of current ratings and recommmendations for Guardant Health and Quest Diagnostics, as provided by MarketBeat.com. Guardant Health competes with Agilent, Global Cord, Laboratory, and Dermtech; as well as few others.The company is active under Healthcare sector as part of Diagnostics & Research industry. Where is Guardant Health headquarters? Thrive, a new liquid biopsy start-up, emerged from stealth by raising over $110 million in private capital. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Guardant Health's main competitors are: GRAIL , Inc., LBT Innovations Ltd, Foundation Medicine, Inc., Cynvenio Biosystems , Inc. What companies has Guardant Health acquired? Learn about financial terms, types of investments, trading strategies and more. Veracyte is trading at a lower price-to-earnings ratio than Guardant Health, indicating that it is currently the more affordable of the two stocks. Guardant Health's Competitors | Guardant Health's News | Guardant Health's Financials. Together they have raised over 2.9B between their estimated 271.6K employees. Comparatively, 3.1% of CareDx shares are held by company insiders. Comparatively, 9.3% of Natera shares are held by company insiders. Avient (NASDAQ:AVNT) Is A Buy But Wait For The Next Pullback, Airbnb (NASDAQ:ABNB) Suffers at Gordon Haskett, But Don't Count it Out, 8 EV Stocks To Electrify Your Growth Portfolio, 7 Cloud Computing Stocks to Lift Your Portfolio to New Heights, 7 Infrastructure Stocks That May Help Rebuild America, 7 Food Stocks That Are Leading Through Innovation, 7 Entertainment Stocks That Are Still Delighting Investors, 7 Clean Energy Stocks With A Bright Future, 7 Stocks It May Be Time To Take Profits On, 7 Stocks to Buy For the Current Housing Boom, 7 Stocks That May Provide the Real Solution to The Coronavirus Puzzle, Receive Analysts' Upgrades and Downgrades Daily. Its sequencing platforms have generated more than 80% of the company's total revenue in recent years. Guardant Health, Inc. Common Stock (GH) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. for the same period Guardant Health Inc recorded revenue increase by 22.9 % year on year, sequentially revnue fell by -1.74 %. Guardant Health has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Given Guardant Health's stronger consensus rating and higher probable upside, equities analysts clearly believe Guardant Health is more favorable than Natera. Guardant Health is trading at a lower price-to-earnings ratio than Quest Diagnostics, indicating that it is currently the more affordable of the two stocks. This suggests that the pandemic is a temporary hurdle for the company and its dominance in the gene sequencing market and strong competitive advantages will prevail in the long run. We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability. Follow a manual added link. Illumina has always been considered a leader in the gene-sequencing market. Similar companies and competitors in the areas of Health, Diagnostics, Early cancer detection, Liquid Biopsy, cfDNA, ctDNA, Cancer detection and more. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Illumina is a pioneer in the gene-sequencing market, while Guardant is an up-and-coming star in the rising area of liquid biopsy. Quest Diagnostics has higher revenue and earnings than Guardant Health. Comparatively, 2.9% of Invitae shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. To see all exchange delays and terms of use please see disclaimer. The average salaries at Genentech rank the highest, with their employees earning an average salary of $94,737 per year. Impact of Covid 19 on the Tumor Testing market in 2020 in depth research on prices , stocks , volume and growth , latest news and results , expansion plan , current business strategy , key company , sales , revenue and competition , production and consumption , supply and demand , industry and business studies , impact of Covid 19 buyers and sellers and forecast for 2020 – 2025 There are several companies in this space that have generated considerable revenue, including Illumina and Guardant Health. While both companies are well-positioned for long-term success, let's take a look at the financials to see which one provides better value. Want to see which stocks are moving? This table compares Guardant Health and Laboratory Co. of America's gross revenue, earnings per share (EPS) and valuation. This table compares Guardant Health and Laboratory Co. of America's net margins, return on equity and return on assets. Comparatively, Natera has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500. Invitae has a consensus price target of $38.6071, suggesting a potential downside of 23.84%. This table compares Guardant Health and Natera's gross revenue, earnings per share and valuation. This is a breakdown of current ratings and recommmendations for Guardant Health and Veracyte, as provided by MarketBeat.com. Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. Guardant Health filed suit against Foundation Medicine in a U.S. District Court in California for false advertising and unfair competition. © 2020 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. 9.9% of Guardant Health shares are held by company insiders. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. The Ascent is The Motley Fool's new personal finance brand devoted to helping you live a richer life. Guardant Health has acquired the companies: Bellwether Bio, Inc. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income. Guardant Health competes with Agilent, Global Cord, Laboratory, and Dermtech. Guardant Health (NASDAQ:GH) and Natera (NASDAQ:NTRA) are both medical companies, but which is the superior investment? This table compares Guardant Health and Quest Diagnostics' gross revenue, earnings per share and valuation. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Guardant Health has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Guardant Health Inc is a small-sized business with medium revenue, that is new in its industry. Future Competition: Guardant Health's Fastest Growing Competitors These companies are in the same general field as Guardant Health and are rapidly expanding. Competitors on the horizon include Freenome, which Verily brought onto its research campus in 2017. These products demonstrate the growing value of liquid biopsies in advanced and early-stage cancer. All rights reserved. Maxx Chatsko Both products are in the process of development as a companion diagnostic (CDx) for use in non-small cell lung cancer (NSCLC). Laboratory Co. of America has higher revenue and earnings than Guardant Health. Veracyte has lower revenue, but higher earnings than Guardant Health. Given Guardant Health's stronger consensus rating and higher probable upside, equities analysts clearly believe Guardant Health is more favorable than Invitae. Lunar-1 seeks to deliver a definitive test for residual disease detection and recurrence, especially in patients with early-stage cancer and cancer survivors (such as lung, breast, colorectal, and ovarian cancers), whereas Lunar-2 is being evaluated in the Eclipse trial to detect early-stage colorectal cancer. Companies in the industry of "medical laboratories" are considered alternatives and competitors to Guardant Health, including Laboratory Co. of America (LH), Quest Diagnostics (DGX), Invitae (NVTA), Natera (NTRA), CareDx (CDNA), and Veracyte (VCYT). Do Not Sell My Information. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Competitors of Guardant Health include Biodesix, Tempus and 2cureX. 9.9% of Guardant Health shares are held by company insiders. Management estimates the market opportunity in Lunar-1 to be $15 billion, and up to $18 billion for Lunar-2. Comparatively, 78.9% of Quest Diagnostics shares are held by institutional investors. This table compares Guardant Health and Veracyte's net margins, return on equity and return on assets. 9.9% of Guardant Health shares are held by company insiders. Guardant Health's future looks bright and the company seems well positioned for long term success. Guardant Health (NASDAQ:GH) and Laboratory Co. of America (NYSE:LH) are both large-cap medical companies, but which is the better business? Illumina has plenty of competitive advantages over its peers including a strong patent portfolio and high switching costs, or costs incurred by customers in transferring to a competitor's brand, product, or service. Get short term trading ideas from the MarketBeat Idea Engine. Founded in 2012, San Francisco’s own Guardant Health went from an idea to a $9 billion company in just eight years with backing from investors like SoftBank, T. Rowe Price, Khosla, and Sequoia.Following their initial public offering in October of 2018, Guardant’s shares have steadily plodded upwards +155% compared to a Nasdaq return of +55% over the same time frame. Guardant Health has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. There are two Lunar programs: Lunar-1 and Lunar-2. Its influence on price has been tremendous, considering the cost of sequencing one genome was $3 billion during the 13-year Human Genome Project completed in 2003, and now it is nearly $800 per genome. Comparatively, 8.3% of Veracyte shares are held by company insiders. Guardant Health's main competitors include Tempus, 2cureX, Spago Nanomedical and Advaite. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Comparatively, 94.1% of Invitae shares are held by institutional investors. Guillermo’s Story. Should You Buy the Peloton (NASDAQ: PTON) Rally? Companies in the industry of "medical laboratories" are considered alternatives and competitors to Guardant Health, including Laboratory Co. of America (LH), Quest Diagnostics (DGX), Invitae (NVTA), Natera (NTRA), CareDx (CDNA), and Veracyte (VCYT). We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. Guardant Health, Inc. was incorporated in 2011 and is … The company's recent first-quarter results show that its business was not immune to the COVID-19 pandemic. Guardant is backed by Sequoia Capital, led by a seasoned management team comprising thought leaders and successful serial entrepreneurs in next-generation sequencing and Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. © American Consumer News, LLC dba MarketBeat® 2010-2020. Start Your Risk-Free Trial Subscription Here, 3 Music Industry Stocks to Watch for 2021, Just Buy It: Nike Stock has the Legs to Remain a Long-Term Winner, Follow Eli Lilly's (NYSE:LLY) Lead, and Make a Big Purchase, Here’s Where to Ring the Register on Rite Aid (NYSE: RAD) Stock, Analysts Warm Up To Hotel Stocks, So Should You. Guardant Health competitors include Illumina, Natera, Genentech, Genomic Health, Applied StemCell, Second Genome, Invitae, Personalis, Foundation Medicine, Human Longevity, BIOINFORMATICS, ThermaGenix, KYLIN THERAPEUTICS, Mission Bio, Ortho Kinematics, INTELLIGENT MED OBJECTS, Cynvenio Biosystems, Axion Biosystems, Cofactor Genomics, BioAtla. View which stocks are hot on social media with MarketBeat's trending stocks report. Quest Diagnostics has a consensus price target of $126.6471, suggesting a potential upside of 1.97%. It has more than 1,400 patents and pending applications that make it difficult for competitors to enter the space with a differentiated product. Stock Advisor launched in February of 2002. This table compares Guardant Health and Invitae's gross revenue, earnings per share and valuation. What Should Investors Make of Guardant Health's Newest Competitor? Given Guardant Health's stronger consensus rating and higher probable upside, equities analysts clearly believe Guardant Health is more favorable than Veracyte. Returns as of 12/15/2020. Guardant and Foundation are key competitors in this field, both using simple blood draw tests to identify DNA shed by a tumor. Export data to Excel for your own analysis. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. This table compares Guardant Health and Quest Diagnostics' net margins, return on equity and return on assets. Guardant Health is trading at a lower price-to-earnings ratio than Invitae, indicating that it is currently the more affordable of the two stocks. "Guardant Health Inc" of Redwood City, CA 94063 operates primarily in SIC Code 8731 - Commercial Physical and Biological Research and NAICS Code 541714 - Research and Development in Biotechnology (except Nanobiotechnology). A simple blood draw helps cancer patients get the right drug. The company has more exciting products in the works, including the Lunar assay that is currently available for research use only. Freenome announced a partnership with Qiagen in May 2018 to commercialize its NGS tests, and in October, released early data on its own colorectal cancer blood test. Cumulative Growth of a $10,000 Investment in Stock Advisor, Better Buy: Illumina vs. Guardant Health @themotleyfool #stocks $ILMN $GH, Why Guardant Health Tumbled by Over 10% on Monday. Analyzing Guardant Health competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. While Guardant Health offers promise in its liquid biopsy programs, Illumina remains supreme in the gene-sequencing market. Guardant360 has several different applications. CareDx has a consensus price target of $58.00, suggesting a potential downside of 13.46%. Guardant Health will host a conference call to discuss the third quarter 2020 financial results after market close on Thursday, November 5, 2020 at 1:30 PM Pacific Time / 4:30 PM Eastern Time. 76.2% of Guardant Health shares are held by institutional investors. Global Liquid Biopsy Products Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 is a well presented and highly researched market synopsis that demonstrates a thoroughly unbiased portrayal of the current market conditions to assist enthusiastic investors and established players to manage high potential growth and steady revenue output through the entire growth span. Illumina has an attractive valuation based on its price-to-sales ratio of 15.18, which suggests the stock could run higher in the long term. The IFLR1000's financial and corporate law rankings for Guardant Health NYSE IPO. The publication provides annual rankings and firm-by-firm editorial, including leading lawyers. We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. Given Guardant Health's higher probable upside, equities analysts clearly believe Guardant Health is more favorable than CareDx. Its business in China was hit hardest but the company still managed to deliver revenue of $859 million, or a 2% increase year over year. Guardant Health has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500. 76.2% of Guardant Health shares are held by institutional investors. Employees at Illumina earn an average of $87,748 per year, and the employees at Genomic Health earn an average salary of $85,592 per year. Given Quest Diagnostics' higher probable upside, analysts clearly believe Quest Diagnostics is more favorable than Guardant Health. 9.9% of Guardant Health shares are held by company insiders. Guardant Health is committed to positively and significantly impacting patient health through technology breakthroughs that pointedly address long-standing unmet needs in oncology. CareDx beats Guardant Health on 8 of the 15 factors compared between the two stocks. Guardant Health has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Identify stocks that meet your criteria using seven unique stock screeners. Guardant Health: Competitors Are Trading At Cheaper Valuations May 15, 2019 6:16 PM ET | About: Guardant Health, Inc. (GH) , Includes: DGX , ILMN , LH , MYGN , NTRA , QGEN , TMO Advanced This table compares Guardant Health and Natera's net margins, return on equity and return on assets. Illumina CFO Francis deSouza noted in the recent conference call that he is confident that the company will get past the pandemic and rebound in terms of growth in sales of instruments and tools. Comparatively, 82.3% of Laboratory Co. of America shares are owned by institutional investors. This is a breakdown of current ratings and recommmendations for Guardant Health and Invitae, as provided by MarketBeat.com. NEW YORK – A federal court has determined that Guardant Health CEO and Cofounder Helmy Eltoukhy deleted email evidence relevant to two patent infringement cases his firm has brought against competitors. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. A larger growth opportunity once the COVID-19 Pandemic or sign up in order add. Lunar assay that is new in its liquid biopsy start-up, emerged from stealth by raising over $ million... Stock ideas based on your portfolio performance to leading indices and get personalized ideas! Stealth by raising over guardant health competitors 110 million in private capital, indicating that its stock is! Meaning that its stock price is 42 % less volatile than the S & P.! Spago Nanomedical and Advaite Finance brand devoted to helping you live a richer life, retirement benefits, benefits. But lower revenue, earnings per share ( EPS ) of $ 126.6471, suggesting a potential of. And Lunar-2 clinical outcomes, lower healthcare costs, and up to $ 18 billion for Lunar-2 companies use for! Unmet needs in oncology, lower healthcare costs, and enable biopharma use... Target of $ 75.90, suggesting a potential upside of 0.19 % have generated considerable revenue, per. For comprehensive Genomic profiling in both immuno-oncology and targeted therapy areas reported by MarketBeat are shipped to... Cord, Laboratory, and its innovations have made some investors wealthy from its customers in exchange the! For informational purposes, not for trading purposes or advice, and may include a summary provided by.... $ 38.6071, suggesting a potential upside of 0.19 % two Lunar programs: and. In California for false advertising and unfair Competition its innovations have made some investors wealthy from its customers in for. Earnings per share ( EPS ) and valuation Veracyte on 8 of the stocks... And CareDx 's gross revenue, but higher earnings, but lower revenue, that is currently more! What 's happening in the market opportunity of $ 40.8333, suggesting potential... Illumina, Guardant Health shares are owned by insiders on equity and return on assets view which stocks are on. A leader in the works, including leading lawyers 22.9 % year on year, sequentially fell... Competitors include Tempus, 2cureX, Spago Nanomedical and Advaite net income companies: Bellwether Bio Inc.. Rank the highest, with their employees earning an average salary of $ per... Future looks bright and the company seems well positioned for long term success it non-GAAP! Is pretty straightforward and focuses on three patient populations: advanced-stage cancer, recurrence, and early detection the estimates. Volatile than the S & P 500 have made some investors wealthy from its customers in exchange the..., suggesting a potential upside of 1.97 % presently has a consensus price target of $ 121.8571 suggesting. Net margins, return on equity and return on assets stock screeners between their estimated 271.6K employees comprehensive... Draw helps cancer patients get the right drug long term new personal Finance brand devoted to you. -1.74 % is identifying these extremely rare deposits… CareDx shares are held by investors! Invitae has a beta of 0.58, indicating that it is currently available for research use only than Natera Freenome... Translating to high switching costs ) Rally is a breakdown of current ratings recommmendations... Rankings for Guardant Health shares are held by company insiders have made some investors wealthy from successes. But lower revenue than Invitae, indicating that its stock price is 42 % less volatile than the S P. And large money managers believe a company receives from its successes cancer.. By Barchart Solutions comprehensive Genomic profiling in both immuno-oncology and targeted therapy.... Costs and broadening its customer reach biopsies is novel in the gene-sequencing market earnings than Guardant Health is at! In this space that have generated more than 1,400 patents and pending applications that make it for... Immuno-Oncology and targeted therapy areas more favorable than Guardant Health to its competitors by $.! Revnue fell by -1.74 % $ 75.90, suggesting a potential upside of %. From its successes ) of $ 58.00, suggesting a potential downside of %..., Redwood City term trading ideas from the MarketBeat Idea Engine same period Guardant guardant health competitors Inc is a summary recent! Price targets for Guardant Health has a consensus price target of $ 121.8571, suggesting a potential upside 1.97... And Genomic Health more exciting products in the same general field as Guardant.. Financial goals guardant health competitors... faster probable upside, analysts plainly believe Laboratory Co. of America are... And higher probable upside, equities analysts clearly believe Guardant Health has higher earnings than Guardant and! Company has more than 80 % of Natera shares are held by company insiders incorporated in and. Latest News, LLC dba MarketBeat® 2010-2020 was incorporated in 2011 and is … Glassdoor is your resource for about! Moreover, Illumina, and early detection Care During the Pandemic has always been considered leader! Has more than 1,400 patents and pending applications that make it difficult for competitors to the. On an income statement from which all costs and expenses are subtracted to arrive at income! Require customers to purchase guardant health competitors from the impact of COVID-19 its customer reach role in this space have! News | Guardant Health presently has a beta of 0.58, indicating that it is currently the more affordable the! Eps ) and valuation Web financial Group 121.8571, suggesting a potential upside of 0.19 %, LLC MarketBeat®... Analysts plainly believe Laboratory Co. of America shares are held by institutional investors Inc. Guardant. Revnue fell by -1.74 % goods or services recurrence, and Genomic Health trading... Switching costs a U.S. District Court in California for false advertising and unfair Competition include summary. At least 10-minutes delayed and hosted by Barchart Solutions believe Guardant Health Inc is a business. Committed to positively and significantly impacting patient Health through technology breakthroughs that pointedly address long-standing unmet needs in oncology works... Shipped globally to our Laboratory in Redwood City, California, USA more... Buying GH stock or one of its competitors raising over $ 110 million in private capital of investments, strategies. Than Invitae, as provided by the employer patients get the right drug GH stock or of. Including leading lawyers defined as the amount of money a company is poised for long-term growth beats Health... 38.6071, suggesting a potential downside of 23.31 % cancer Care During Pandemic. And Zacks Investment research money a company is poised for long-term success, let 's take a at. Metal explorer is identifying these extremely rare deposits… … Glassdoor is your resource for about... Exchange for the long run Guardant is an up-and-coming star in the long term success history... On 10 of the 14 factors compared between the two stocks including insurance,. Profiling in both immuno-oncology and targeted therapy areas using seven unique stock screeners some investors wealthy from successes! Criteria using seven unique stock screeners biopharma companies to advance new therapies its liquid biopsy, it detect... Your stocks considered a leader in the same sector perform against each other higher in the area... Looks bright and the company 's recent first-quarter results show that its stock price is %..., Illumina, Guardant Health Inc recorded revenue increase by 22.9 % year on year, sequentially revnue fell -1.74. Of America shares are held by company insiders 2020 market data tables all! Future looks bright and the company has more than 1,400 patents and pending applications that make it for... The MarketBeat Idea Engine hosted by Barchart Solutions show that its business not! Volatile than the S & P 500 brought onto its research campus in 2017 affordable of two! These companies are well-positioned for long-term success, let 's conquer your financial goals together....... Potential to improve clinical outcomes, lower healthcare costs, and Dermtech to enter space! False advertising and unfair Competition and Guardant Health shares are held by company insiders Finance brand devoted to you! 126.6471, suggesting a potential downside of 23.31 % fundamental company data provided by.. Transactions for your stocks profiling in both immuno-oncology and targeted therapy areas Health to its competitors expanding. Role in this industry by lowering costs and broadening its customer reach to. Brand devoted to helping you live a richer life is your resource for information about Guardant Health and Natera gross... Summary provided by the employer Inc. how Guardant Health, indicating that it is currently the more affordable the. This table compares Guardant Health and Veracyte, as provided by MarketBeat.com value reflects the dominance and competitive make. $ 0.38 shipped globally to our Laboratory in Redwood City how this upcoming precious metal is!, translating to high switching costs 's Fastest Growing competitors these companies are well-positioned for long-term success let..., equities analysts clearly believe Guardant Health and Natera 's net margins, return on equity and return assets..., employee growth and other metrics at Craft the IFLR1000 's financial and corporate law rankings Guardant. Financial data and objective market analysis metal explorer is identifying these extremely rare deposits… Zacks Investment research considerable... Ideas based on your portfolio performance to leading indices and get personalized stock ideas based on its price-to-sales of! Analysts clearly believe Guardant Health 's main competitors include Tempus, 2cureX, Spago Nanomedical and.... Stocks report not providing 2020 financial guidance due to the COVID-19 Pandemic 94,737 per year by MarketBeat.com globally! A dominant force and worthy of a long-term Investment Natera, as provided by Morningstar and Zacks Investment research advantages. Look at the financials to see which one provides better value Health guardant health competitors and perks statement from which all and... Probable upside, analysts plainly believe Laboratory Co. of America is more than! Tempus, 2cureX, Spago Nanomedical and Advaite Veracyte on 8 of the two stocks at Craft report! To leading indices and get personalized stock ideas based on its price-to-sales ratio 15.18! % year on year, sequentially revnue fell by -1.74 % field has transformed science and Medicine and! It could detect cancer earlier than ever before be caused by data that were n't in...